about
Strain-dependent embryonic lethality and exaggerated vascular remodeling in heparin cofactor II-deficient miceEffect of aspirin treatment on serum concentrations of lipoprotein(a) in patients with atherosclerotic diseasesVitamin D receptor in osteoblasts is a negative regulator of bone mass controlHeparin cofactor II, a serine protease inhibitor, promotes angiogenesis via activation of the AMP-activated protein kinase-endothelial nitric-oxide synthase signaling pathway.Bovine milk-derived lactoferrin exerts proangiogenic effects in an Src-Akt-eNOS-dependent manner in response to ischemia.Chondromodulin I is a bone remodeling factor.Suppressive function of androgen receptor in bone resorptionEffects of statins on cardiorenal syndrome.Brain masculinization requires androgen receptor function.Heparin cofactor II as a novel vascular protective factor against atherosclerosis.Effects of androgens on cardiovascular remodeling.Vascular smooth muscle cell proliferation is dependent upon upregulation of mitochondrial transcription factor A (mtTFA) expression in injured rat carotid artery.Activation of peroxisome proliferator-activated receptor α in megakaryocytes reduces platelet-derived growth factor-BB in platelets.Inflammation and vascular remodeling.Transforming Growth Factor-β1 as a Common Target Molecule for Development of Cardiovascular Diseases, Renal Insufficiency and Metabolic Syndrome.Interactions between CKD and MetS and the Development of CVD.Inhibition of thrombin action ameliorates insulin resistance in type 2 diabetic db/db mice.Bosentan ameliorated exercise-induced pulmonary arterial hypertension complicated with systemic sclerosis.Heparin cofactor II protects against angiotensin II-induced cardiac remodeling via attenuation of oxidative stress in mice.Dehydroepiandrosterone sulfate is inversely associated with sex-dependent diverse carotid atherosclerosis regardless of endothelial function.Endothelial nitric oxide synthase-independent protective action of statin against angiotensin II-induced atrial remodeling via reduced oxidant injury.Ezetimibe ameliorates metabolic disorders and microalbuminuria in patients with hypercholesterolemia.Decrease in plasma brain natriuretic peptide level in the early phase after the start of carvedilol therapy is a novel predictor of long-term outcome in patients with chronic heart failure.Role of hypoxia-inducible factor 1alpha in T cells as a negative regulator in development of vascular remodeling.Nitrosonifedipine ameliorates angiotensin II-induced vascular remodeling via antioxidative effects.Heparin cofactor II is a novel protective factor against carotid atherosclerosis in elderly individuals.Disruption of nuclear vitamin D receptor gene causes enhanced thrombogenicity in mice.Serum carboxy-terminal telopeptide of type I collagen (ICTP) as a surrogate marker for vulnerable plaques in atherosclerotic patients: a pilot study.Androgen-androgen receptor system protects against angiotensin II-induced vascular remodeling.Infective endocarditis caused by lactobacillus.Pitavastatin, an HMG-CoA reductase inhibitor, exerts eNOS-independent protective actions against angiotensin II induced cardiovascular remodeling and renal insufficiency.Isolated high-molecular-weight kininogen deficiency: a novel frameshift mutation in exon 10.Heparin cofactor II is an independent protective factor against peripheral arterial disease in elderly subjects with cardiovascular risk factors.High plasma heparin cofactor II activity is associated with reduced incidence of in-stent restenosis after percutaneous coronary intervention.High plasma aldosterone concentration is a novel risk factor of cognitive impairment in patients with hypertension.Deferoxamine promotes angiogenesis via the activation of vascular endothelial cell function.Plasma heparin cofactor II activity is inversely associated with left atrial volume and diastolic dysfunction in humans with cardiovascular risk factors.[Vitamin D-vitamin D receptor system regulates antithrombogenicity in vivo]Intra-vascular ultrasound findings of diffuse coronary atherosclerotic change in systemic lupus erythematosus with secondary antiphospholipid syndromeImprovement of cardiac diastolic function and prognosis after autologous peripheral blood stem cell transplantation in AL cardiac amyloidosis
P50
Q24680458-1F4E0C46-A60E-4751-B4B9-D6331BA8C7D9Q28193646-4A35F4F5-F92C-4C20-BE7B-89C0328F6995Q28285124-A8BA51B8-FB85-473D-9255-EA70CF7A4291Q34384055-86637706-BD59-4672-A588-4B59AB5974F9Q34567904-16D97FD8-2D16-4F50-A875-428C3394D9D4Q34811184-ACAABF4F-5DED-41B6-9A83-1BCB72E0C917Q35234694-57F0D62B-8368-459C-ABE6-0A7F8DDBB32AQ36077149-C0200ECF-A7DE-48B2-B826-64B01D10D3A1Q36161347-55102271-83E6-4BE6-BCCC-B70B70844C89Q37591730-52EA7F78-9B5B-4196-9382-5957C0D40C05Q38001674-71711DAE-AAFB-4CB1-89C3-10534A24EB13Q38333392-64E6E672-1FBD-45EB-87FA-03726712BF7FQ39634344-494EF4E9-F48A-41E4-8CBE-C9C1CD3E662EQ41732107-047060EF-BD27-46E5-A149-18AE37A4C585Q41811073-6158D2F2-7062-434E-AF85-E01E10966FAFQ42737191-2F806252-5836-4831-922D-6E8EF1B9D4B6Q42831553-AC881F8A-88CF-42A9-8492-F7B5D2FF54CDQ42837427-7CB2616A-7021-49AB-8E45-6D5A16130449Q42957310-06D9F2F3-F9CB-4726-A47E-26BEC67A94A2Q42971652-E4F5C82A-5C1A-4911-82BA-70337BF6198EQ43145685-7933C0D5-264A-400A-8BDC-5C8A1C53150AQ43164610-EA108661-61ED-49EA-B158-3E447774843DQ43199506-4D8C4A34-F25D-4D27-BF26-8B3A09B03CA4Q43223140-CE020D54-F1D4-4826-8D06-79C4386AD4BBQ44612476-84FC6389-D0E0-4369-82E0-477ACD6D215BQ44899715-DC557107-F569-4AC2-B954-A0FF070E13DEQ44942856-D755DA0C-8223-488E-A723-897767F383D3Q45375516-DC1B0C95-EA6B-443A-AB41-ADCC84DBA38AQ46131656-8915643E-E034-479E-A854-2135DE587996Q46541308-F911CE55-E15E-48B8-8BC6-4EA20CF3AF38Q46925640-58304011-46FD-4BA8-BEE9-8A3BEEF2F5F9Q47286820-D3141F3D-64C5-408F-AA7D-0D51B7D75B23Q47914323-D3F36F68-EB9C-40C2-A4F9-56DFB786277DQ51718785-3D7B7523-FBCE-4A17-94BE-8BBBE05DC515Q51837355-D0DD1E1F-10DF-4FE1-8C2D-5116B3B91A55Q54613591-974AA7D2-DCFE-4E2B-86BA-1AD9FF9DB778Q55053632-811A741B-08BF-4C90-BD1D-99F17896DA04Q79829061-0DA29156-5F30-4A77-9401-8326290F48FBQ79976576-505365C3-203E-4B4B-A556-E63234DE8926Q81445290-65FEA9AE-F909-4DD2-B161-FAA875AD2D49
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Ken-ichi Aihara
@ast
Ken-ichi Aihara
@en
Ken-ichi Aihara
@es
Ken-ichi Aihara
@nl
Ken-ichi Aihara
@sl
type
label
Ken-ichi Aihara
@ast
Ken-ichi Aihara
@en
Ken-ichi Aihara
@es
Ken-ichi Aihara
@nl
Ken-ichi Aihara
@sl
prefLabel
Ken-ichi Aihara
@ast
Ken-ichi Aihara
@en
Ken-ichi Aihara
@es
Ken-ichi Aihara
@nl
Ken-ichi Aihara
@sl
P106
P31
P496
0000-0001-8906-0920